Cellebrite (NASDAQ: CLBT) posts Q1 2026 growth and issues 2026 guidance
Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Cellebrite DI Ltd. reported strong growth for the first quarter of 2026. Revenue rose to $128.3 million from $107.5 million, driven mainly by subscription services, which increased to $96.5 million. GAAP net income declined to $10.9 million from $17.4 million as operating expenses rose.
On a non-GAAP basis, operating income improved to $28.6 million and adjusted EBITDA increased to $30.6 million, with an adjusted EBITDA margin of 23.9%. The company highlighted annual recurring revenue growth of 21% and a trailing 12‑month free cash flow margin of 32%, reflecting a cash‑generative subscription model.
For the second quarter of 2026, Cellebrite expects ARR of $510–$513 million and revenue of $130–$133 million, with adjusted EBITDA of $29–$31 million. Full‑year 2026 guidance calls for ARR of $567–$573 million, revenue of $565–$571 million, and adjusted EBITDA of $149–$155 million, implying healthy profitability and continued growth.
Insights
Software & SaaS equities analyst neutral
High growth SaaS profile with rising costs but strong cash generation.
Cellebrite is showing classic subscription scale: Q1 2026 revenue grew to $128.3M, with subscription services at $96.5M. Annual recurring revenue grew 21%, reinforcing a durable, contract-based revenue base attractive in software models.
Profitability is mixed. GAAP net income fell to $10.9M as research, sales, and G&A spending increased, but non-GAAP operating income and adjusted EBITDA improved to $28.6M and $30.6M, respectively. A trailing 12‑month free cash flow margin of 32% underlines efficient cash conversion despite higher operating expenses.
Guidance targets 2026 ARR of $567–$573M and revenue of $565–$571M, with adjusted EBITDA margins of 26–27%. This points to continued growth with solid margins, though execution on new product adoption and maintaining retention will be key as reflected in their emphasis on ARR acceleration through 2026.
Key Figures
Q1 2026 Revenue:
$128.3M
Q1 2026 GAAP Net Income:
$10.9M
Q1 2026 Adjusted EBITDA:
$30.6M
+5 more
8 metrics
Q1 2026 REVENUE
$128.3M
For the three months ended March 31, 2026
Q1 2026 GAAP NET INCOME
$10.9M
For the three months ended March 31, 2026
Q1 2026 ADJUSTED EBITDA
$30.6M
Adjusted EBITDA for Q1 2026
TTM FREE CASH FLOW MARGIN
32.0%
Trailing 12 months ended March 31, 2026
2026 REVENUE GUIDANCE
$565M–$571M
Full-year 2026 expectations as of May 14, 2026
2026 ADJUSTED EBITDA GUIDANCE
$149M–$155M
Full-year 2026 expectations as of May 14, 2026
Q1 2026 FREE CASH FLOW
$16.8M
Free cash flow for the three months ended March 31, 2026
Q1 2026 GROSS MARGIN
82.5%
Gross margin for the three months ended March 31, 2026
Key Terms
annual recurring revenue, adjusted EBITDA, free cash flow, non-GAAP financial measures, +2 more
6 terms
Annual Recurring Revenue
FINANCIAL
Adjusted EBITDA
FINANCIAL
Free Cash Flow
FINANCIAL
Non-GAAP Financial Measures
FINANCIAL
Dollar-Based Net Retention Rate
FINANCIAL
Forward-Looking Statements
REGULATORY
Find StockTitan more easily in Google Search and AI answers.
Adds StockTitan as a preferred source · opens Google
Add on Google
Not now
Form 6-K: How Foreign Companies Report to the SEC →
05/14/2026 - 07:15 AM
⛶ Fullscreen
Source:
View Original Filing on SEC EDGAR
FAQ
How did Cellebrite (CLBT) perform financially in Q1 2026?
Cellebrite delivered solid Q1 2026 growth, with revenue rising to $128.3 million from $107.5 million. Subscription services contributed $96.5 million, and gross profit reached $105.9 million. However, higher operating expenses reduced GAAP net income to $10.9 million from $17.4 million.
What were Cellebrite’s profitability metrics for Q1 2026?
Cellebrite’s GAAP operating income was $9.1 million, down from $12.3 million. On a non-GAAP basis, operating income rose to $28.6 million, and adjusted EBITDA increased to $30.6 million, yielding an adjusted EBITDA margin of 23.9%, compared with 22.0% a year earlier.
What guidance did Cellebrite (CLBT) give for Q2 2026?
For Q2 2026, Cellebrite expects ARR of $510–$513 million with annual growth of 22–23%. Revenue is projected at $130–$133 million, implying 15–17% growth, and adjusted EBITDA is forecast at $29–$31 million with margins of 22–23%.
What is Cellebrite’s full-year 2026 outlook for revenue and ARR?
For full-year 2026, Cellebrite projects ARR of $567–$573 million, reflecting 18–19% annual growth. Revenue is expected between $565 million and $571 million, with annual growth of 19–20%, supported by adjusted EBITDA of $149–$155 million and margins of 26–27%.
How strong is Cellebrite’s free cash flow generation?
Cellebrite reported Q1 2026 free cash flow of $16.8 million, compared with $18.5 million a year earlier. Over the trailing twelve months ended March 31, 2026, free cash flow totaled $158.6 million, corresponding to a free cash flow margin of 32.0%, indicating robust cash generation.
How did Cellebrite’s balance sheet look at March 31, 2026?
As of March 31, 2026, Cellebrite held $133.7 million in cash and cash equivalents, plus significant short-term deposits and marketable securities. Total assets were $952.3 million and shareholders’ equity was $510.5 million, providing a substantial capital base to support ongoing growth initiatives.
Filing Exhibits & Attachments
1 document
PRESS RELEASES
EX-99.1
PRESS RELEASE TITLED "CELLEBRITE ANNOUNCES FIRST-QUARTER 2026 RESULTS"
179.9 KB